Skip to content
Screener

Design Therapeutics, Inc. DSGN Interest Income

Interest Income at other companies

ALN
Alnylam PharmaceuticalsALNY
$28.14M+2.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$5.8M-21.7%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$8.76M+23.3%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$3.16M+168%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$2.33M+25.1%
Vor Biopharma logo
Vor BiopharmaVOR
$3.94M+389%

Other financials

Income statement

See full
Revenue-—
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$896.8M+227%
Enterprise value$886.76M+245%

Profitability

See full
Operating margin-3,685.8%—
Net margin-3,663.7%—

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0×0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.

Filed
Apr 28, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-187063
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Research and development (including related party amounts of $72 and $228, respectively)$14,379$15,377
General and administrative (including related party amounts of $85 and $134, respectively)5,3275,041
Total operating expenses19,70620,418
Loss from operations(19,706)(20,418)
Interest income2,0702,703
Net loss$(17,636)$(17,715)
Net loss per share, basic and diluted$(0.29)$(0.31)
Weighted-average shares of common stock outstanding, basic and diluted61,434,45756,757,827

Item 1. Financial Statements.

FAQ

What is Design Therapeutics, Inc.'s interest income?
Design Therapeutics, Inc. (DSGN) reported interest income of $2.07M in Q1 2026.
How has Design Therapeutics, Inc.'s interest income changed year-over-year?
Design Therapeutics, Inc.'s interest income decreased by 23.4% year-over-year, from $2.7M to $2.07M.
What is the long-term trend for Design Therapeutics, Inc.'s interest income?
Over 2 years (2023 to 2025), Design Therapeutics, Inc.'s interest income has grown at a -7.6% compound annual growth rate (CAGR), from $11.33M to $9.68M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Design Therapeutics, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude